Mechanism
Semaglutide is a long-acting GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is an incretin hormone normally released by intestinal L-cells in response to a meal. It does several things at once: it stimulates glucose-dependent insulin secretion from the pancreas, suppresses glucagon, slows gastric emptying, and acts centrally on the hypothalamus to reduce appetite.
The native peptide has a half-life of about 2 minutes. Semaglutide is engineered with a fatty-acid side chain that allows it to bind albumin and resist enzymatic degradation, giving it a half-life of approximately 7 days. This is what makes once-weekly subcutaneous dosing feasible.
The molecular target — the GLP-1 receptor — is highly conserved, well-characterized, and present in pancreatic beta cells, the gastrointestinal tract, the central nervous system, and the cardiovascular system. The breadth of receptor distribution explains both the breadth of clinical effects and the breadth of adverse events.
What the evidence shows
The evidence base for semaglutide is unusual in its scale. Selected pivotal trials:
- SUSTAIN-1 through SUSTAIN-10 (2016–2020): Multi-site RCTs in type 2 diabetes establishing efficacy on HbA1c and weight versus placebo and active comparators. Consistent ~1.5% reduction in HbA1c at the 1mg dose.
- STEP-1 through STEP-5 (2021–2022): Multi-site RCTs in obesity (BMI ≥30, or ≥27 with comorbidity) showing approximately 15% mean weight loss at 2.4mg weekly versus 2.4% with placebo.
- SUSTAIN-6 (2016): Cardiovascular safety trial in T2D showing reduced major adverse cardiovascular events.
- SELECT (2023): Cardiovascular outcomes trial in non-diabetic patients with overweight/obesity and pre-existing cardiovascular disease. Showed 20% relative risk reduction in MACE.
- FLOW (2024): Renal outcomes trial showing reduced kidney-disease progression in T2D with chronic kidney disease.
The evidence is not perfect. The trials are predominantly in patients with established disease; effects in metabolically healthy individuals are extrapolated, not measured. The long-term effects of semaglutide in patients without indication — increasingly common given off-label demand — are not well characterized. We do not have multi-decade follow-up.
But the depth of the data on the populations the drug was designed for is substantial. This is why the verdict is Established.
Dosing literature
Approved dosing (subcutaneous, once weekly):
- Type 2 diabetes (Ozempic): 0.25mg → 0.5mg → 1mg → 2mg, with 4-week dose-escalation steps to manage GI tolerability
- Obesity (Wegovy): 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg, again with 4-week escalation steps
Oral semaglutide (Rybelsus) is also available for diabetes; bioavailability is low and food-timing rules are strict (taken on an empty stomach, with limited water, then no food for 30 minutes).
Off-label dosing in obesity has used ranges up to 2.4mg in patients without diabetes. We do not have evidence supporting doses higher than the approved maxima.
The titration discipline matters. Skipping titration steps to chase faster weight loss is the most common cause of severe nausea, vomiting, and discontinuation.
Risks and adverse events
Common: Nausea (~40% at therapeutic doses), vomiting (~15%), diarrhea, constipation, abdominal pain. Most are dose- and time-dependent and improve with slower titration.
Less common but important:
- Gastroparesis-like syndrome — slowed gastric emptying that can persist; concerning for patients undergoing anesthesia (food in the stomach during induction)
- Acute pancreatitis — case reports; relative risk debated, but the signal is real enough that any abdominal pain warrants assessment
- Gallbladder disease — increased rate of cholelithiasis, particularly with rapid weight loss
- Diabetic retinopathy worsening — observed in SUSTAIN-6 in patients with pre-existing retinopathy and rapid HbA1c improvement
Pre-clinical / theoretical: Medullary thyroid C-cell tumors in rodents; not observed in humans, but contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2.
Self-sourced semaglutide adds risks not present with the FDA-approved product: counterfeit or misdosed compounds, contamination, dosing errors from imprecise reconstitution, and absence of clinical monitoring for the adverse events above.
Regulatory status
| Region | Diabetes | Obesity | Notes |
|---|---|---|---|
| United States | Approved (Ozempic, Rybelsus) | Approved (Wegovy) | DEA: not scheduled. Off-label compounding has been restricted as of 2025 once shortages resolved. |
| European Union | Approved | Approved | Same brand names. |
| United Kingdom | Approved | Approved | NHS access criteria apply. |
| Canada | Approved | Approved | |
| Australia | Approved | Approved |
Regulatory status changes occasionally; this row is reviewed every 12 months.
Where to get it
The honest path: a clinician relationship, an FDA-approved (or equivalent) product, and a pharmacy. Self-sourcing semaglutide is a category of decision we do not endorse, even where it is technically legal. The dose-titration discipline, the GI tolerability management, and the monitoring for the less-common adverse events listed above are real reasons to involve a clinician.
We have no fulfillment partner for semaglutide at this time. (See How we make money — the absence of a partner link is a deliberate signal, not an oversight.)
References (selected)
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016 (SUSTAIN-6). PubMed
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021 (STEP-1). PubMed
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023 (SELECT). PubMed
- Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024 (FLOW).
- FDA prescribing information, Ozempic and Wegovy — current revisions.
Quick Facts
| Also Known As | NN9535, Ozempic, Wegovy, Rybelsus |
|---|---|
| Sequence | His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly |
| Molecular Formula | C187H291N45O59 |
| Molecular Weight | 4114 Da |
| PubChem CID | 56843331 |
Research Parameters
| Half-Life | ~165 hours (approximately 1 week) |
|---|---|
| Stability | Lyophilized powder is stable for 24 months when stored at -20°C. After reconstitution in bacteriostatic water, the solution is stable for up to 56 days when stored refrigerated at 2-8°C. The commercial injectable solution (Ozempic/Wegovy pens) is stable for the duration indicated on the product labeling when refrigerated; it can be kept at room temperature (below 30°C) for a limited period (e.g., 56 days). |
| Solubility | Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Water for Injection. The commercial product is supplied as a ready-to-use solution. |
| Storage (Lyophilized) | -20°C, protect from light and moisture. For long-term storage, keep desiccated. |
| Storage (Reconstituted) | 2-8°C (refrigerated), protected from light. Do not freeze. Use within the stability period (e.g., 56 days). |
| Typical Research Dose | 250-1000 mcg once weekly (for research analogs; clinical doses are in mg: 0.25 mg, 0.5 mg, 1.0 mg, 2.4 mg) |
| Cycle Parameters | In clinical research, administration is continuous once weekly via subcutaneous injection, often with a 4-week dose-escalation phase. Studies typically last from 30 weeks to over 2 years to assess long-term efficacy and safety. No standard 'cycle' with off-periods is used; it is a chronic therapy. |
| Amino Acid Count | 31 |
Mechanism of Action
Semaglutide exerts its primary effects through selective, high-affinity agonism at the glucagon-like peptide-1 receptor (GLP-1R), a G-protein coupled receptor widely expressed in pancreatic islets, the brain, heart, and gastrointestinal tract. Activation of GLP-1R triggers intracellular signaling cascades, primarily via adenylate cyclase and cAMP production, leading to a suite of glucose-dependent and weight-regulating actions.
Pancreatic Beta-Cell Insulin Secretion: Semaglutide enhances glucose-stimulated insulin secretion from pancreatic beta cells in a glucose-dependent manner. The increased intracellular cAMP potentiates the exocytosis of insulin granules, improving postprandial glycemic control without causing hypoglycemia during fasting states.
Pancreatic Alpha-Cell Glucagon Suppression: The peptide suppresses the inappropriate postprandial secretion of glucagon from pancreatic alpha cells. By lowering glucagon levels, it reduces hepatic glucose production, contributing to overall blood glucose lowering.
Central Appetite Regulation: Semaglutide crosses the blood-brain barrier in limited amounts and activates GLP-1 receptors in key hypothalamic and brainstem nuclei involved in satiety regulation, such as the arcuate nucleus. This leads to reduced appetite, increased feelings of fullness, and decreased food intake, which is the primary driver of its weight loss effects.
Gastric Emptying Delay: It slows gastric emptying by acting on receptors in the stomach and vagal afferents. This delay increases gastric distension and enhances nutrient contact with intestinal L-cells, further promoting satiety signals and blunting postprandial glucose excursions.
Cardiovascular and Renal Pathways: Beyond metabolic effects, GLP-1 receptor activation in cardiovascular tissues may improve endothelial function, reduce inflammation, and exert direct cardioprotective effects. In the kidneys, it may promote natriuresis and have renoprotective actions, though these mechanisms are still under investigation.
Research Applications
Type 2 Diabetes Management: Semaglutide has been extensively researched for glycemic control. Clinical trials consistently demonstrate significant reductions in HbA1c (often by 1.5-2.0%) and body weight. Its once-weekly formulation improves adherence, and its cardiovascular outcome trials have shown non-inferiority or superiority in reducing MACE compared to placebo, making it a preferred agent in patients with cardiovascular disease.
Obesity and Weight Management: As an anti-obesity medication, semaglutide research shows profound weight loss efficacy, with average reductions of 15-20% of body weight in clinical trials. Its mechanism of reducing appetite and caloric intake addresses the physiological regulation of body weight, positioning it as a transformative pharmacotherapy for chronic weight management.
Non-Alcoholic Steatohepatitis (NASH): Preclinical and clinical research indicates semaglutide may improve histological features of NASH, including reducing liver fat content, inflammation, and ballooning. Its benefits are attributed to weight loss and direct anti-inflammatory and anti-fibrotic effects on hepatocytes and hepatic stellate cells.
Cardiovascular Disease: Research extends to cardiovascular benefits independent of glycemic control. Studies suggest improvements in blood pressure, lipid profiles, and markers of inflammation and endothelial dysfunction. The SUSTAIN 6 trial demonstrated a significant reduction in cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
Neurodegenerative Disorders: Emerging preclinical research explores the potential neuroprotective effects of GLP-1 receptor agonists like semaglutide in models of Alzheimer's and Parkinson's disease. Proposed mechanisms include reducing neuroinflammation, promoting synaptic plasticity, and enhancing neuronal survival, though this remains an investigational area.
Safety & Side Effects
The most common adverse effects reported in animal and human clinical studies are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, which are generally mild to moderate in severity and tend to diminish over time. These effects are dose-dependent and related to the peptide's action on gastric emptying and central nausea centers. Anecdotally, reports of fatigue, headache, and dyspepsia have also been noted. Serious but rare theoretical concerns include the risk of medullary thyroid carcinoma (observed in rodent studies with chronic, supra-therapeutic dosing, relevance to humans is unclear) and acute pancreatitis. Hypoglycemia risk is low when used without insulin or sulfonylureas due to its glucose-dependent mechanism. Injection site reactions are possible. Research subjects are typically monitored for these events.
Dosage Information
Disclaimer: The following information is derived from published clinical research and is presented for educational purposes only. It does not constitute medical advice.
In clinical research for type 2 diabetes, semaglutide is typically initiated at a dose of 0.25 mg once weekly subcutaneously for 4 weeks, then escalated to a maintenance dose of 0.5 mg or 1.0 mg once weekly. For chronic weight management, the dosing protocol involves a gradual titration over 16-20 weeks from 0.25 mg/week to a target dose of 2.4 mg/week to improve gastrointestinal tolerability. The primary route of administration in most studies is subcutaneous injection. An oral formulation (Rybelsus) is also used in research, with doses ranging from 3 mg to 14 mg taken daily on an empty stomach. The duration of administration in long-term trials often extends for one year or more to assess sustained efficacy and safety.
References
Marso, S.P., et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2016.
Davies, M., et al. Efficacy and Safety of Semaglutide Compared with Dulaglutide and Exenatide ER in Type 2 Diabetes. Lancet Diabetes & Endocrinology, 2017.
Wilding, J.P.H., et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021.
Lau, J., et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry, 2015.
Aroda, V.R., et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Type 2 Diabetes. Diabetes Care, 2019.
Kushner, R.F., et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity, 2020.
Newsom, S.A., et al. A Pilot Study Investigating the Effects of a GLP-1 Analog on Exercise Performance. Journal of Clinical Endocrinology & Metabolism, 2020.